BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang S, Yang Y, Ma P, Huang H, Tang Q, Miao H, Fang Y, Jiang N, Li Y, Zhu Q, Tao W, Zha Y, Li N. Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials. Mol Ther Oncolytics 2022;24:799-813. [PMID: 35317518 DOI: 10.1016/j.omto.2022.02.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Famta P, Shah S, Jain N, Kumar KC, Bagasariya D, Khatri DK, Raghuvanshi RS, Singh SB, Srivastava S. Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer. Life Sciences 2022;310:121125. [DOI: 10.1016/j.lfs.2022.121125] [Reference Citation Analysis]
2 Filiberti S, Russo M, Lonardi S, Bugatti M, Vermi W, Tournier C, Giurisato E. Self-Renewal of Macrophages: Tumor-Released Factors and Signaling Pathways. Biomedicines 2022;10:2709. [DOI: 10.3390/biomedicines10112709] [Reference Citation Analysis]
3 Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol 2022;13:954992. [DOI: 10.3389/fimmu.2022.954992] [Reference Citation Analysis]
4 Wang X, Cheng W, Zeng X, Dou X, Zhou Z, Pei Q. EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer. Front Immunol 2022;13:987394. [DOI: 10.3389/fimmu.2022.987394] [Reference Citation Analysis]
5 Sun Q, Liu Q, Zhou X, Wang X, Li H, Zhang W, Yuan H, Sun C. Flavonoids regulate tumor-associated macrophages - From structure-activity relationship to clinical potential (Review). Pharmacol Res 2022;184:106419. [PMID: 36041653 DOI: 10.1016/j.phrs.2022.106419] [Reference Citation Analysis]
6 Maravajjala KS, Swetha KL, Roy A. pH-responsive nanoparticles for multidimensional combined chemo-immunotherapy of cancer. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.05.008] [Reference Citation Analysis]